timothy sykes logo
ENVB Stock Spikes As New U.S. Patent Fuels Trading Momentum Thumbnail
ADD US ONG Google News

ENVB Stock Spikes As New U.S. Patent Fuels Trading Momentum

MATT MONACO•UPDATED APR. 20, 2026, 9:18 AM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Enveric Biosciences Inc. stocks have been trading up by 135.16 percent amid heightened investor optimism and positive market sentiment

Candlestick Chart

Live Update At 09:17:59 EDT: On Monday, April 20, 2026 Enveric Biosciences Inc. stock [NASDAQ: ENVB] is trending up by 135.16%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

ENVB is trading like a classic low-float biotech with a fresh catalyst. On the daily chart, Enveric Biosciences has mostly chopped between roughly $1.80 and $2.10 over recent weeks, with closes clustering near $1.90–$2.05. That range-bound action set up a tight base before today’s patent news hit the tape.

The intraday tape tells the real story. ENVB sat around $1.90 in the early premarket, then erupted above $4 just after 07:20 as traders discovered the new U.S. patent headline. That’s a 100%+ spike in less than an hour, classic momentum behavior for ENVB-style small-cap biosciences names. Volatility expanded sharply, with wide 5‑minute candles and big wicks showing both aggressive buying and fast profit-taking.

Fundamentally, Enveric Biosciences is still an early-stage story. Revenue is not the focus yet; pipeline and cash are. The latest report shows about $4.68M in cash against total liabilities of only $0.92M, plus a strong current ratio around 5.4. ENVB runs lean with just six employees but reports steep negative returns on equity and assets, a reminder this is a capital-burning R&D play, not a cash cow.

Why Traders Are Watching ENVB After The New Patent

ENVB just delivered the type of catalyst active traders hunt for. Enveric Biosciences announced a new U.S. patent covering its EVM301 series, including lead neuroplastogen EB-003. That patent extends protection over a family of non-hallucinogenic neuroplastogenic molecules aimed at neuropsychiatric and addiction disorders. In plain English: ENVB is trying to rewire brain circuits like psychedelics do, but without the trip.

For biotech traders, patents matter. This move locks in intellectual property around EVM301 and EB-003 right as Enveric Biosciences prepares an IND filing and a Phase 1 trial. That sequence — patent, IND prep, early human data — is a classic de-risking arc for a tiny biotech. ENVB is still highly speculative, but each legal and regulatory milestone makes the story more concrete.

The mental-health angle also helps the trading narrative. ENVB now has explicit patent protection for molecules being developed to treat mental health disorders and addiction, two enormous markets that Wall Street follows closely. When headlines tie “new U.S. patent,” “neuropsychiatric,” and “addiction” to a low-priced ticker like ENVB, momentum traders notice.

Today’s premarket surge from sub‑$2 to above $4 shows exactly that. ENVB became a momentum magnet as traders chased the breakout, scalped the swings, and watched for halts. Short-term, this is more about supply and demand than long-term valuation. But underneath the spike, the patent win gives Enveric Biosciences a firmer strategic base as it pushes EB-003 toward first-in-human testing. For pattern-based traders who also respect fundamentals, that combo is powerful.

More Breaking News

Conclusion

ENVB now sits at a crossroads between story and execution. On one side, Enveric Biosciences has locked down a new U.S. patent for its EVM301 series, including EB-003, securing years of protection around its non-hallucinogenic neuroplastogenic platform. That IP build-out, paired with plans for an IND and Phase 1 trial in neuropsychiatric and addiction disorders, gives traders a clear forward map of potential catalysts.

On the other side, the financials remind everyone what ENVB really is: a cash-burning, pre-revenue biosciences name. Enveric Biosciences carries roughly $4.68M in cash, minimal debt, and heavy operating losses of over $2.1M in the latest quarter. Negative returns on equity and assets are brutal, but typical for a micro-cap biotech still years from commercial products. The balance sheet buys time, not certainty.

For active traders, ENVB is now on the watchlist as a high-volatility, catalyst-driven ticker. The patent headline has already triggered one major squeeze; future moves will likely track any updates on EB-003, the EVM301 series, and regulatory filings. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your preparation.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. For ENVB, that means studying the chart, knowing the catalyst, and treating every trade as a planned trade — not a hope-and-pray bet.

This coverage of ENVB and Enveric Biosciences is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading ENVB

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”